Payment overview · 2025
General Payments
$427.46
17 reported records · 8 companies
Healthcare provider profile · identity verified
Jorge Orellana, MD
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLYN, NY · NPI 1346203569
Verified facts
What the public records show
CMS Open Payments records show Jorge Orellana, MD received $427.46 in general payments during 2025 across 17 reported records.
Exact Sciences Corporation accounted for 32.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 299 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 274 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $140.71 | 32.9% | 5 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $64.38 | 15.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.76 | 14.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $57.77 | 13.5% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $39.60 | 9.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.14 | 5.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.13 | 5.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.97 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $427.46 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $140.71 | 5 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $64.38 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.76 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $57.77 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $39.60 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.24 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.14 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.02 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 100 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 274 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
299 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
100 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
220 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
274 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 951 | 211 |
| Gabapentin | Gabapentin | 617 | 132 |
| Metformin Hcl | Metformin Hcl | 489 | 96 |
| Amlodipine Besylate | Amlodipine Besylate | 429 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 377 | 68 |
| Ammonium Lactate | Ammonium Lactate | 369 | 86 |
| Omeprazole | Omeprazole | 328 | 65 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 302 | 62 |
| Jardiance | Empagliflozin | 299 | 55 |
| Ozempic | Semaglutide | 274 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 252 | 56 |
| Lisinopril | Lisinopril | 248 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 246 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 242 | 56 |
| Trulicity | Dulaglutide | 220 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 214 | 54 |
| Valsartan | Valsartan | 212 | 48 |
| Chlorthalidone | Chlorthalidone | 186 | 41 |
| Nifedipine Er | Nifedipine | 180 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 178 | 36 |
| Losartan Potassium | Losartan Potassium | 178 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 41 |
| Alendronate Sodium | Alendronate Sodium | 171 | 35 |
| Famotidine | Famotidine | 159 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 157 | 33 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 155 | 39 |
| Simvastatin | Simvastatin | 155 | 35 |
| Donepezil Hcl | Donepezil Hcl | 137 | 28 |
| Montelukast Sodium | Montelukast Sodium | 137 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 122 | 32 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 111 | 19 |
| Mounjaro | Tirzepatide | 100 | 20 |
| Furosemide | Furosemide | 99 | 25 |
| Novolog Flexpen | Insulin Aspart | 96 | 17 |
| Celecoxib | Celecoxib | 90 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 20 |
| Mirtazapine | Mirtazapine | 80 | 16 |
| Eliquis | Apixaban | 79 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 79 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 77 | 16 |
| Azelastine Hcl | Azelastine Hcl | 75 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 23 |
| Tresiba Flextouch U-100 | Insulin Degludec | 74 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 73 | 21 |
| Vascepa | Icosapent Ethyl | 73 | 12 |
| Entresto | Sacubitril/Valsartan | 71 | 15 |
| Glipizide Er | Glipizide | 66 | 16 |
| Tresiba Flextouch U-200 | Insulin Degludec | 64 | suppressed |
| Ezetimibe | Ezetimibe | 62 | 21 |
| Januvia | Sitagliptin Phosphate | 62 | suppressed |
| Carvedilol | Carvedilol | 57 | 12 |
| Meclizine Hcl | Meclizine Hcl | 56 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 52 | 16 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 51 | 13 |
| Allopurinol | Allopurinol | 50 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 50 | 11 |
| Sertraline Hcl | Sertraline Hcl | 49 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 16 |
| Ibuprofen | Ibuprofen | 48 | suppressed |
| Linzess | Linaclotide | 48 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 47 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 46 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 44 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 43 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 43 | suppressed |
| Spironolactone | Spironolactone | 42 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 39 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Finasteride | Finasteride | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 16 |
| Synjardy | Empagliflozin/Metformin Hcl | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Topiramate | Topiramate | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Calcitriol | Calcitriol | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 11 |
| Latanoprost | Latanoprost | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Indapamide | Indapamide | 29 | suppressed |
| Lactulose | Lactulose | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 26 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 19 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Isoniazid | Isoniazid | 17 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 15 | suppressed |
| Cholestyramine Light | Cholestyramine | 15 | suppressed |
| Comfort Ez Pro Safety Pen Ndl | Pen Needle, Diabetic, Safety | 15 | suppressed |
| Crestor | Rosuvastatin Calcium | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Albendazole | Albendazole | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Glipizide Xl | Glipizide | 13 | suppressed |
| Methimazole | Methimazole | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vasotec | Enalapril Maleate | 13 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $427.46 · 17 records | Exact Sciences Corporation | BEXSERO, BREZTRI, Cologuard Collection Kit, GVOKE HYPOPEN, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, MOUNJARO, Ozempic, REZDIFFRA, Rybelsus, SHINGRIX, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error